W. Burny

发表

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

J. Vermylen, B. Maillère, K. Peerlinck, 2003, Blood.

Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection

A. Marchant, C. Donner, C. Liesnard, 2004, Expert review of anti-infective therapy.

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

R. A. van den Berg, A. Callegaro, A. Marchant, 2017, Front. Immunol..

Effect of callus development on the deformation of external fixation frames

F. Burny, M. Donkerwolcke, W. Burny, 2012, International Orthopaedics.

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data

Ehrenstein, I. Bruce, Jane Worthington, 2018, RMD Open.

Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.

A. Didierlaurent, C. Hervé, W. Burny, 2022, Vaccine.

Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

P. van Damme, U. D'Oro, O. Finco, 2021, NPJ vaccines.

Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR.

P. Stordeur, D. de Groote, B. Byl, 2005, Journal of immunological methods.

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

Francisco Bonachela Capdevila, I. Bruce, Jane Worthington, 2022, Scientific Data.

Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.

A. Callegaro, C. Legrand, A. Marchant, 2019, Vaccine.

Immune monitoring in whole blood using real-time PCR.

T. van der Poll, M. Goldman, P. Stordeur, 2003, Journal of immunological methods.

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Functional Exhaustion Limits CD4+ and CD8+ T-Cell Responses to Congenital Cytomegalovirus Infection.

V. Appay, A. Marchant, C. Donner, 2015, The Journal of infectious diseases.

Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The Gambia.

S. Rowland-Jones, H. Whittle, P. Kaye, 2008, The Journal of infectious diseases.

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.

T. Harrer, J. van Lunzen, G. Fätkenheuer, 2014, Vaccine.

Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses

R. A. van den Berg, M. Demoitié, M. Coccia, 2022, PloS one.

Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients.

G. Leroux-Roels, L. Vandekerckhove, P. Moris, 2014, Journal of immunological methods.

Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice

P. Lebrun, J. Cosyns, W. Burny, 1997, Lupus.

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

TRIAL A phase I / II trial of the safety and clinical activity of a HER 2-protein based immunotherapeutic for treating women with HER 2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016 .

Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design

D. Lauffenburger, A. Essaghir, Corinne Luedemann, 2023, npj Vaccines.

Injections of Complexes made of dsDNA and Specific Polyclonal Antibodies Extend MRL LPR Mouse Survival: a Pilot Study

P. Lebrun, J. Cosyns, W. Burny, 1994, Lupus.

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

I. Carletti, P. van Damme, P. Kremsner, 2016, Clinical immunology.

Impact of adjuvants on CD 4 + T cell and B cell responses to a protein antigen vaccine : Results from a phase II , randomized , multicenter trial

I. Carletti, P. Kremsner, A. Marchant, 2016 .

Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature

R. A. van den Berg, A. Smilde, A. Callegaro, 2020, Science Translational Medicine.

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

E. Jongert, O. Ofori-Anyinam, M. Hatherill, 2015, Vaccine.

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine

A. Callegaro, M. Levin, A. Cunningham, 2021, The Journal of infectious diseases.

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

Francisco Bonachela Capdevila, J. Sergeant, A. Cuza, 2022, Scientific Data.

Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial

J. van Beek, A. Buisman, L. Beckers, 2024, Nature communications.

Multiple vaccine comparison in the same adults from the VITAL study reveals vaccine-specific and age-related humoral response patterns.

D. Baarle, A. Buisman, L. Beckers, 2024, medRxiv.

Functional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine

A. Didierlaurent, R. G. van der Most, W. Burny, 2024, Science Translational Medicine.

Adjuvant system AS01: from mode of action to effective vaccines.

M. Coccia, W. Burny, Lucile Warter, 2024, Expert review of vaccines.